Evidence map›Paper›PMID 37425211›Full record

ArticleJHEP reports : innovation in hepatology2023

Endogenous sex steroid hormones and risk of liver cancer among US men: Results from the Liver Cancer Pooling Project.

Zeni Wu, Jessica L Petrick, Andrea A Florio, Chantal Guillemette, Laura E Beane Freeman, Julie E Buring, Gary Bradwin, Patrick Caron, Yu Chen, A Heather Eliassen and 28 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 14 institutions in 2 countries.

Zeni WuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Jessica L PetrickSlone Epidemiology Center, Boston University, Boston, MA, USA.
Andrea A FlorioDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Chantal GuillemettePharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec-(CHU de Québec) Research Center-Université Laval, Québec, QC, Canada.
Laura E Beane FreemanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Julie E BuringDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Gary BradwinClinical and Epidemiologic Research Laboratory, Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, USA.
Patrick CaronPharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec-(CHU de Québec) Research Center-Université Laval, Québec, QC, Canada.
Yu ChenDepartment of Population Health, New York University School of Medicine, New York, NY, USA.
A Heather EliassenDepartment of Epidemiology, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Lawrence S EngelDepartment of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
Neal D FreedmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
J Michael GazianoDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Edward L GiovannuciDepartment of Epidemiology, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Jonathan N HofmannDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Wen-Yi HuangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Victoria A KirshOntario Institute for Cancer Research, Toronto, ON, Canada.
Cari M KitaharaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Jill KoshiolDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
I-Min LeeDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Linda M LiaoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Christina C NewtonDepartment of Population Science, American Cancer Society, Atlanta, GA, USA.
Julie R PalmerSlone Epidemiology Center, Boston University, Boston, MA, USA.
Mark P PurdueDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Thomas E RohanDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, NY, USA.
Lynn RosenbergSlone Epidemiology Center, Boston University, Boston, MA, USA.
Howard D SessoDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Rashmi SinhaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Meir J StampferDepartment of Epidemiology, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Caroline Y UmDepartment of Population Science, American Cancer Society, Atlanta, GA, USA.
Stephen K Van Den EedenDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Kala VisvanathanBloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Jean Wactawski-WendeDepartment of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY, USA.
Anne Zeleniuch-JacquotteDepartment of Population Health, New York University School of Medicine, New York, NY, USA.
Xuehong ZhangDepartment of Nutrition, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Barry I GraubardDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Peter T CampbellAlbert Einstein College of Medicine, New York, NY, USA.
Katherine A McGlynnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
National Cancer Institute · USBrigham and Women's Hospital · USBoston University · USAlbert Einstein College of Medicine · USAmerican Cancer Society · USCentre hospitalier universitaire de Québec · CANew York University · USBoston Children's Hospital · USHarvard University · USJohns Hopkins University · USKaiser Permanente · USOntario Institute for Cancer Research · CAUniversity at Buffalo, State University of New York · USUniversity of North Carolina at Chapel Hill · US

Funding

Studies of Rare CancersZIACP010158 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MCGLYNN, KATHERINE · 2009 to 2025
$19.1M
6 · The paper itself

Abstract

Background & Aims: Incidence rates of liver cancer in most populations are two to three times higher among men than women. The higher rates among men have led to the suggestion that androgens are related to increased risk whereas oestrogens are related to decreased risk. This hypothesis was investigated in the present study via a nested case-control analysis of pre-diagnostic sex steroid hormone levels among men in five US cohorts. Methods: Concentrations of sex steroid hormones and sex hormone-binding globulin were quantitated using gas chromatography-mass spectrometry and a competitive electrochemiluminescence immunoassay, respectively. Multivariable conditional logistic regression was used to calculate odds ratios (ORs) and 95% CIs for associations between hormones and liver cancer among 275 men who subsequently developed liver cancer and 768 comparison men. Results: Higher concentrations of total testosterone (OR per one-unit increase in log Conclusions: Higher concentrations of both androgens (testosterone, dihydrotestosterone) and their aromatised oestrogenic metabolites (oestrone, oestradiol) were observed among men who subsequently developed liver cancer compared with men who did not. As DHEA is an adrenal precursor of both androgens and oestrogens, these results may suggest that a lower capacity to convert DHEA to androgens, and their subsequent conversion to oestrogens, confers a lower risk of liver cancer, whereas a greater capacity to convert DHEA confers a greater risk. Impact and implications: This study does not fully support the current hormone hypothesis as both androgen and oestrogen levels were associated with increased risk of liver cancer among men. The study also found that higher DHEA levels were associated with lower risk, thus suggesting the hypothesis that greater capacity to convert DHEA could be associated with increased liver cancer risk among men.

Indexed as

AndrogenLiver cancerMaleOestrogenSex steroid hormone

Identifiers

PMID37425211
PMCPMC10326694
OpenAlexW4353096527

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.